Lipocine announces plans to price public offering of its common stock

Bookrunner Ladenburg Thalmann, lead manager National Securities assist

By Devika Patel

Knoxville, Tenn., Nov. 4 - Lipocine Inc. will price a public sale of common stock, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

Ladenburg Thalmann & Co. Inc. is the sole bookrunning manager, and National Securities Corp. is the lead manager.

Proceeds will be used to conduct clinical trials for LPCN 1021 and other product candidates and the balance for working capital and other general corporate purposes.

The specialty pharmaceutical company is based in Salt Lake City.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.